Spotlight On... CutisPharma adds drug manufacturing to its operations; JHL secures Affinita contract; India's Odisha state wants to attract API manufacturers; and more...

CutisPharma, a specialty pharma company with a background in selling kits used by retail pharmacies to compounded medications, has now gotten into the manufacturing side of things itself. The company Wednesday kicked off new manufacturing operations at its Wilmington, MA headquarters. A spokesman said CutisPharma invested $4 million in the FDA GMP compliant facility and is in the process of hiring. It has already added 15 people, bringing its total to 50, and expects to add up to 100 more as its moves for FDA approval of applications for generic drugs. It has worked with contract manufacturers in the past, the spokesman said. Release

> JHL Biotech says it has an agreement with Affinita Biotech to provide cell line development, process development, and manufacturing at JHL's Zhubei site in Taiwan and its manufacturing facility in Wuhan, China for Affinta's oncology monoclonal antibodies. Release (PDF)

> Patheon signed a deal with German drugmaker Grünenthal to help develop abuse-deterrent formulations of controlled substances. More

> India's Odisha state plans to build industrial parks for manufacturing APIs. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)